Pacific Biosciences of California, Inc.

Day range

$2.08 – $2.31

Open

$2.12

Prev close

$2.11

Volume

9.56M

Market cap

$655.85M

Shares out

310.83M

P/E

—

P/S

4.12

P/B

-19.75

P/FCF

—

ROE

395.6%

ROA

-17.5%

Debt/Equity

-19.40

Div yield

0.00%

As of Oct 23, 2026

• Ceo appointmentAug 5, 2026

  On July 30, 2026, the Board appointed Mark Van Oene, age 54, as the Company's President and Chief Executive Officer and as a member of the Board, effective August 5, 2026 (the "Effective Date"). In connection with his appointment as Chief Executive Officer, the Company and Mr. Van Oene entered into an employment agreement (the "Employment Agreement"). The terms of the Employment Agreement provide that Mr. Van Oene will receive an annual base salary of $743,000, effective August 16, 2026.

• Director departureJul 9, 2026

  On July 8, 2026, Christopher M. Smith, a member of the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the "Company"), notified the Company of his resignation from the Board, effective immediately.

• Equity compensation grantJun 4, 2026

  the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the "Company"), at the recommendation of the compensation committee of the Board, approved an amendment (the "Amendment") to the Company's 2020 Equity Incentive Plan (the "2020 Plan"), subject to stockholder approval, to reserve an additional 16,000,000 shares of the Company's common stock (the "Additional Shares") for issuance pursuant to the 2020 Plan.

• Executive officer departureMar 6, 2026

  On March 2, 2026, Michele Farmer notified Pacific Biosciences of California, Inc. (the "Company") that she is voluntarily resigning as Chief Accounting Officer of the Company effective on March 21, 2026, to pursue another opportunity. Ms. Farmer's departure is not in connection with any known disagreement with the Company on any matter relating to its operations, policies, or practices.

• Director appointmentMar 5, 2026

  the Board of Directors (the "Board") of Pacific Biosciences of California, Inc. (the "Company"), upon the recommendation of its Corporate Governance and Nominating Committee, increased the size of the Board to ten directors and appointed Christopher Gibson, Ph.D. to serve as a Class I director effective as of the Effective Date, with an initial term expiring at the Company's 2026 annual meeting of stockholders. As of the Effective Date, the Board also appointed Dr. Gibson as a member of the Company's Science and Technology Committee.

• TXG10x Genomics, Inc. Class A Common Stock+1.97%

Days to cover

3.0

Short interest

47.22M

Avg volume

15.91M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
  negativeZacks Investment Research· Oct 14, 2026
• PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
  positiveZacks Investment Research· Oct 13, 2026
• Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
  negativeZacks Investment Research· Oct 8, 2026
• Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR
  positiveGlobeNewswire Inc.· Oct 5, 2026
• Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
  negativeZacks Investment Research· Oct 2, 2026